Table 1.
Patient demographic and clinical characteristics in the astrocytic and oligodendroglial tumor cohorts*
| Astrocytoma | Grade II | Grade III | Grade IV | All |
|---|---|---|---|---|
| No. of patients | 114 | 59 | 503 | 676 |
| Sex (n) | ||||
| Male | 82 | 38 | 287 | 407 |
| Female | 32 | 21 | 216 | 269 |
| Age, y | ||||
| Median (mean ± SD) | 46 (46 ± 16) | 50 (52 ± 17) | 65 (65 ± 13) | |
| Minimum | 12 | 23 | 4 | |
| Maximum | 83 | 84 | 90 | |
| Follow-up | ||||
| No. of survivors at the end of follow-up | 25 | 6 | 9 | |
| Follow-up duration for survivors, mo (median [mean ± SD]) | 92 (108 ± 77) | 141 (142 ± 80) | 59 (98 ± 69) | |
| 5-y survival rate, % | 58 | 32 | 3.4 | |
| Tumors (n) | ||||
| Primary | 81 | 41 | 414 | |
| Second recidive | 25 | 13 | 69 | |
| Third recidive | 8 | 4 | 17 | |
| Fourth-sixth recidive | 0 | 1 | 2 | |
| Oligodendroglial tumor | O II | O III | OA II | OA III |
| No. of patients | 38 | 33 | 23 | 22 |
| Sex (n) | ||||
| Male | 19 | 17 | 12 | 8 |
| Female | 19 | 16 | 11 | 14 |
| Age, y | ||||
| Median (mean ± SD) | 45 (45 ± 12) | 57 (57 ± 10) | 52 (46 ± 17) | 42 (46 ± 15) |
| Minimum | 26 | 38 | 5 | 25 |
| Maximum | 69 | 72 | 64 | 74 |
| Follow-up | ||||
| No of survivors at the end of follow-up | 25 | 9 | 9 | 4 |
| Follow-up duration for survivors, mo (median [mean ± SD]) | 83 (106 ± 64) | 96 (66 ± 50) | 94 (161 ± 121) | 203 (221 ± 114) |
| 5-y survival rate, % | 79 | 43 | 84 | 50 |
| Tumors (n) | ||||
| Primary | 34 | 21 | 19 | 18 |
| Second recidive | 4 | 10 | 4 | 4 |
| Third recidive | 0 | 1 | 0 | 0 |
| Fourth-sixth recidive | 0 | 1 | 0 | 0 |
Abbreviations: O, oligodendroglioma, OA, oligoastrocytoma.
*Patient age and follow-up information were calculated using primary cases. Follow-up times are shown in months (mo).